The clinical and microbiological effectiveness of a single dose of oral fosfomycin trometamol is comparable to that of comparator antibiotics, as is safety, in women with confirmed or suspected acute uncomplicated cystitis, a recent study has shown. Use of fosfomycin trometamol is also associated with high patient compliance.
Paediatric patients with neurogenic bladder may benefit from intradetrusor abobotulinum toxin A, which has been shown to improve cystometric capacity and maximum neurogenic detrusor overactivity in a recent study. This effect persists over multiple injections.
Use of mid-urethral tension-free vaginal tape slings leads to better satisfaction and cure rates in women with primary stress urinary incontinence compared with polyacrylamide hydrogel injection, according to a study. However, complication risks are higher with tension-free vaginal tape.
Treatment with abiraterone acetate (AA) or enzalutamide (ENZ) may lead to excess short-term mortality in elderly prostate cancer with pre-existing cardiovascular diseases (CVDs), reports a recent study.
Aquablation performs as well as transurethral resection of prostate (TURP) in terms of safety and efficacy for treating benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS), although the former is associated with a lower rate of retrograde ejaculation, according to the results of a systematic review.
The efficacy and compliance related to percutaneous tibial nerve stimulation (PTNS) are both favourable in traditionally underserved patients treated for overactive bladder at a large urban safety net hospital, reports a study.
Whole-pelvis radiotherapy (WPRT) improves biochemical recurrence-free survival (bRFS), but not distant metastasis-free survival (DMFS) and prostate cancer-specific survival (PCSS), in patients with Gleason grade group 5 prostate cancer (PCa) treated with either external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT), a recent study has found.
Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.